Batavia Biosciences Joins NXTGEN Hightech Program, to Advance Cell and Gene Therapy 

Batavia Biosciences Joins NXTGEN Hightech Program, to Advance Cell and Gene Therapy 

Leiden, January 9, 2024 – Batavia Biosciences, a contract development and manufacturing organization, is excited to announce its active participation in the NXTGEN Hightech Biomedical program. The NXTGEN Hightech program brings together many partners across several domains to deliver structural and sustainable economic growth in The Netherlands and contribute to solutions for societal challenges in health care, energy transition, safety and food. By joining the NXTGEN Hightech program, Batavia Biosciences is committed to advancing the cell and gene therapy field. 

The NXTGEN Hightech is a National Growth Fund program that aims to strengthen The Netherlands’ position as global leader in high-tech innovation. NXTGEN Hightech is a major investment in the future of the national economy and brings together over 330 partners across disciplines. It is a bold and ambitious program that has the potential to make a real difference in the world.

Wilfried Bakker, Director Science & Innovation at Batavia Biosciences, adds: “At the core of the program is Batavia Biosciences’ key focus on the development of environmentally friendly, reproducible, sustainable and cost-effective manufacturing technologies for new therapies in high demand.”

Addressing the critical aspect of cell culturing in the development of cell and gene therapies, this biomedical program emphasizes the need for new equipment and materials to improve process control. Batavia Biosciences is actively involved in this project with the goal of facilitating the adoption of sensor technology by pharmaceutical and biotech companies, which is critical for guaranteeing reproducible and lower-cost manufacturing for new therapies. This includes advancements and demonstration of sensors in a production setting, playing a crucial role for the evaluation of the innovative technologies.

Batavia Biosciences has a strong track record of offering state-of-the-art development and manufacturing solutions for viral vectors and is an integral player in the cell and gene therapy field. Its extensive experience in bioprocessing makes Batavia Biosciences a valuable partner in demonstrating new sensor technologies in a production environment.

Menzo Havenga, CEO Batavia Biosciences, concludes: “Beyond collaboration, the company is dedicated to being a driving force in the NXTGEN consortium, actively shaping the future of production and process technologies for life-changing therapies.”

About NXTGEN Hightech 

This project is made possible in part by a contribution from the National Growth Fund program NXTGEN Hightech. This program will invest as much as € 1 billion until 2030 with over 330 partners, in more than 60 projects and in six essential domains. In doing so, NXTGEN Hightech will make a significant contribution to the structural and sustainable economic growth in the Netherlands and offer solutions for the major societal challenges in the areas of energy transition, health, safety and food.  

For more information, please visit www.nxtgenhightech.nl 

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Thermostable viral envelope protein formulation

Maximizing protein expression